Skip to main content
. 2019 Nov 14;14:256. doi: 10.1186/s13023-019-1239-6

Fig. 1.

Fig. 1

Reported efficacy of bevacizumab for HOCF by HHT centers. Bar color represents response selected by respondent (e.g. 75–100% of patients treated at their center had improvement in cardiac index and heart failure symptoms) and bar height reports the number of centers responding with that category for a given question. CI, cardiac index; HF, heart failure